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Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with a complex etiology in which environmental
factors within a genetically susceptible host maneuver the innate and adaptive arms of the immune system toward
recognition of autoantigens. This ultimately leads to joint destruction and clinical symptomatology. Despite the
identification of a number of disease-susceptibility regions across the genome, RA’s major genetic linkage remains
with the major histocompatibility complex (MHC), which contains not only the key immune-response class I and
class II genes but also a host of other loci, some with potential immunological relevance. Inside the MHC itself,
the sole consistent RA association is that with HLA-DRB1, although this does not encode all MHC-related sus-
ceptibility. Indeed, in a set of Japanese patients with RA and a control group, we previously reported the presence
of a second RA-susceptibility gene within the telomeric human leukocyte antigen (HLA) class III region. Using
microsatellites, we narrowed the susceptibility region to 70 kb telomeric of the TNF cluster, known to harbor four
expressed genes (IkBL, ATP6G, BAT1, and MICB). Here, using numerous single-nucleotide polymorphisms (SNPs)
and insertion/deletion polymorphisms, we identify the second RA-susceptibility locus within the HLA region, as
the T allele of SNP 96452 (T/A), in the promoter region (position 562) of the IkBL gene ( ). This 562T/Pp .0062
A SNP disrupts the putative binding motif for the transcriptional repressor, dEF1, and hence may influence the
transcription of IkBL, homologous to IkBa, the latter being a known inhibitor of NFkB, which is central to innate
immunity. Therefore, the MHC may harbor RA genetic determinants affecting the innate and adaptive arms of the
immune system.
Introduction
Rheumatoid arthritis (RA [MIM 180300]) is one of the
most common autoimmune diseases with a complex ge-
netic etiology. It is characterized by chronic inflammatory
symptoms, such as rheumatoid nodules, vasculitis, and
scleritis. From an immunological standpoint, RA has re-
mained a paradigm for the study of autoimmunity. The
prevalence of RA has been almost constant in the world
population, ranging from 0.3% to 1.0% (Felson 1996).
The degree of the genetic component in RA has been
estimated on the basis of the relative recurrence risk, ls,
for siblings of probands with RA. It is likely that the ls
value lies between 5 and 10 (Seldin et al. 1999; Jawaheer
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et al. 2001). Intense research both in humans and in nat-
urally obtained or genetically engineered rodent models
has put forth several interesting pathophysiological mod-
els in which it appears that both arms of the immune
system, innate and adaptive, intervene in disease patho-
genesis within a genetically susceptible host (for reviews,
see Feldmann et al. 1996; Jirholt et al. 2001). The asso-
ciation betweenHLA-DRB1 alleles encoding the “shared
epitope” (SE) and susceptibility to RA is widely recog-
nized (Gregersen et al. 1987) despite that the actualmech-
anism by which these alleles and/or this epitope confers
susceptibility to RA remains to be established. In the
past few years, several genomewide linkage analyses
documented a number of RA-susceptibility loci, scat-
tered across the human genome. Despite some discrep-
ancies (as often occur) between these studies, the chro-
mosome 6p21.3 human leukocyte antigen (HLA) region
consistently emerged as the major RA-susceptibility lo-
cus in most of them (Cornelis et al. 1998; Jawaheer et
al. 2001; MacKay et al. 2002).
The humanmajor histocompatibility complex (MHC),
alternatively named “HLA,” encompasses 3.6 Mb of
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Figure 1 Physical map of the 70-kb critical segment for the
RA-susceptibility gene between TNFa and C1-2-A. Exons are rep-
resented by blackened boxes; genomic segments that do or do not
contain SNP in the sequenced regions are represented by unblack-
ened boxes or half-blackened boxes, respectively. Arrows indicate
transcriptional orientation. The upper bar indicates the distance (in
kb) from TNFa. Cent. p centromere; Tel. p telomere.
DNA on the short arm of chromosome 6 and is divided
into three regions (in order from centromere to telo-
mere): class II, class III, and class I (MHC Sequencing
Consortium 1999). The MHC is one of the most (if
not the most) densely gene-packed segments of the hu-
man genome and contains, besides the antigen-pre-
senting MHC class I and class II molecules, 1100 other
expressed genes, spread across the entire class II, class
III, and class I segments (Shiina et al. 1999). Therefore,
it is possible, if not highly probable, that some of these
non-HLA genes influence the development of RA, since
it is clear that not all patients with RA carry the SE
of HLA-DRB1 alleles (Dizier et al. 1993; McDaniel
et al. 1995; Teller et al. 1996). In our search for such
a putative “second locus,” we recently screened, using
a panel of microsatellite markers, the entire HLA re-
gion, in a group of Japanese patients with RA and
control individuals. This effort led to the identification
of a second, HLA-DRB1–independent RA-suscepti-
bility locus at the telomeric end of the HLA class III
region, almost 1 Mb away fromHLA-DRB1. This was
corroborated by independent research that indicated
the existence of a second RA-susceptibility locus at the
telomeric end of the HLA region (Zanelli et al. 2001;
Jawaheer et al. 2002). The 70-kb stretch of DNA that
we previously identified is adjacent to the TNF gene
cluster (TNFA and LTA) and is bordered by two micro-
satellites, TNFa and C1-2-A (fig. 1) (Ota et al. 2001b).
In this RA critical segment, four expressed genes have
thus far been identified (in order from centromere to
telomere): IkBL (inhibitor of kB-like protein; also known
as “NFKBIL1”), ATP6G (a member of the vacuolar
ATPase G subunit family), BAT1 (HLA-B–associat-
ed transcript 1; a member of the DEAD-box family
of RNA-binding proteins), and MICB (MHC class I
chain-related gene B) (Browning and McMichael 1996;
MHC Sequencing Consortium 1999; Neville and Camp-
bell 1999; Bahram 2000).
In the present study, to pinpoint the RA-susceptibility
sequence within these four candidate genes, we con-
ducted association analysis using relevant intragenic
SNPs and insertion/deletion polymorphisms (indels).One
SNP in the promoter/enhancer region of the IkBL gene
was found to be most strongly associated with RA, hence
providing genetic evidence that the MHC-based IkBL
gene is involved in the development of RA and, from its
similarity to the IkBa gene, indirectly suggesting that the
NFkB pathway is potentially involved in susceptibility to
arthritis.
Subjects and Methods
Subjects
One hundred sixteen patients with RA (19 males and
97 females) (the same patients studied in our microsat-
ellite-based association mapping) (Ota et al. 2001b) and
100 healthy control individuals (43 males and 57 fe-
males) were enrolled in this investigation. Patients and
control individuals were Japanese. All patients were di-
agnosed according to the American Rheumatism Asso-
ciation’s criteria (Arnett et al. 1988). All subjects (pa-
tients and control individuals) agreed to blood donation
and DNA analysis. Genomic DNA from eight of the
unaffected control individuals was subjected to a “sat-
uration” sequence-variation identification, of SNPs and
indels, as described below (see the “Identification and
Genotyping of SNPs and Indels” subsection).
PCR and Sequencing Primers for Identification
and Detection of Sequence Variations
Primers for DNA amplification and sequencing were
designed manually, according to the genomic sequence of
the 70-kb RA target segment between the two micro-
satellites (TNFa and C1-2-A) in the HLA class III region
(Ota et al. 2001b). Repetitive sequences were masked
using the RepeatMasker software (RepeatMasker Web
Server). Nineteen primer pairs (table 1) were designed,
to separately amplify the genomic segments of the IkBL,
ATP6G, and BAT1 genes—namely all of their promoter/
enhancer regions, all of their exons, certain introns (in-
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Table 1
Primers Used for PCR and Sequencing
REGION AMPLIFIED
SEQUENCES
(5′r3′)
Forward Reverse
IkBL:
Promoter GGACAACAACAGGGACAGATC CTCGTTGCTGCAGTCCTC
Promoter GGAGACACTCCAGGCTGG TCCTACGATAGTCTTCTTCCGTC
Exon 1 GAAATTGAATATCATGTACCCGG CACAGTTCACTTCCGTCCTC
Intron 1 CCATGGAACTCTTGGGCT TCTGCCGGGTACATGATATTC
Exon 2 ACCAGCTTATTTCTCAACTATTGG CCAAGGCTGAAGTCCTGAC
Intron 2 GGCGAAAACCCATCTCTTC ACCAATAGTTGAGAAATAAGCTGGT
Intron 2 GAAGAAATCGGTGTAGGCTGTTG GTCAAAGAATTTGGGCACTGC
Exon 3 GCAGCTGTGGATAGCAGT AGTCCCAGCTAACTTCTGCTC
Exon 4 GATGAAAACCACAGCAATGG ACAGGTGATGCCTCCCATG
ATP6G:
Exon 1, intron 1 GATGAGATTGGGAGAGACACTCG AGTCACCCTTACACACCTCACTAG
Exon 2, intron 2, 3′-flanking region AGCGAGAGCACGAATTCC GTGGTGGTAATAGTATCACAGGG
BAT1:
Exon 1, promoter GGAATGTAGTATAACCCTCAAGCC TAAGGAAATAGCGAACCAACTAGG
Exon 2 GTGAAGGCTGTGCTCGTG CTGAGCAACGACAAACACATC
Exons 3 and 4, intron 3 TCTGGAAGTTGGCAAGAACC TCAACACTCTGTTACACCACAGC
Exon 5, intron 5 AATTGGTTTAGCTCAAACAGAGTG CACCATATAGAATTGCCAAAGATC
Exon 6, intron 5 TGGACATAGGCCCCATAAGTC CCTTCTTGGCACTTGAATGAC
Exon 7 AAGCACCTCTGATGGAGTTATTC CATGACCTATGTGATGGGATTTAG
Exons 8–10, introns 8–10 TCTCCCACGTAATGTCTCTCAC TGCCCATGACCTATGTGATG
Exon 11, introns 10 and 11 CAGTGAGTACTGATCTCATGAAACC GCTCTGCAGTCTTAGTCCCATTC
trons 1 and 2 of IkBL, introns 1 and 2 of ATP6G, and
introns 3, 5, and 8–11 of BAT1), and the 3′-flanking
intergenic regions of ATP6G and BAT1 (table 1 and fig.
1). The same primers were also used in the sequencing
of PCR products.
PCR Amplification of Genomic DNA
Genomic DNA from the eight unrelated healthy in-
dividuals described above (see the “Subjects” subsection)
was amplified using the 19 primer pairs, to detect genetic
variations in this RA critical genomic segment. The 20
ml of reaction mixture contained genomic DNA (2 ng),
standard PCR buffer, dNTPs (0.1 mM each), AmpliTaq
Gold (0.1 ml; Applied Biosystems), and the primer pair
(250 nM each primer). PCRs were performed in a Gene-
Amp PCR System 9700 (Applied Biosystems) with an
initial denaturation at 95C for 9 min, followed by 40
cycles at 95C for 30 s, 60C for 30 s, and 72C for 1
min and a final step at 72C for 7 min. For all amplicons,
6 ml of PCR product was run on a 1.5% agarose gel.
Identification and Genotyping of SNPs and Indels
PCR products were used for direct sequencing. Sixty
nanograms of each PCR product was treated with shrimp
alkaline phosphatase (2 U; Amersham) and exonuclease
I (10 U; Amersham) at 37C for 15 min, followed by
incubation at 80C for 15 min for enzymatic inactiva-
tion. Sequencing reactions were performed using the ABI
Prism BigDye Terminator kit (Applied Biosystems) in a
GeneAmp PCR System 9700 with an initial denaturation
at 96C for 30 s, followed by 50 cycles at 96C for 10
s, 50C for 5 s, and 60C for 4 min. Products were
analyzed on an ABI Prism 3700 multicapillary sequencer
(Applied Biosystems). Genetic diversity in the MICB
gene was detected by direct sequencing of PCR products
with the same PCR and sequencing primers as described
elsewhere (Ando et al. 1997; Ota et al. 2001a). Three
SNPs in the upstream region of the TNFA gene (at nu-
cleotide positions 1031, 863, and 857, in order
from the TNFA transcription initiation site) were also
genotyped by direct sequencing of PCR products am-
plified using the primer set described elsewhere (Mat-
sushita et al. 1999).
Microsatellite Genotyping
For the determination of the number of repeats within
C1-2-A and TNFa microsatellites, forward primers were
5′-end labeled with the fluorescent reagent 6-FAM (Gen-
set). PCR primers and amplification conditionswere iden-
tical to those described elsewhere (Jongeneel et al. 1991;
Nedospasov et al. 1991; Udalova et al. 1993; Tamiya et
al. 1998). On PCR completion, products were denatured
at 100C for 5 min, were mixed with formamide-con-
taining stop buffer, and were electrophoresed on capillary
gels with a size-standard marker of GS500 ROX through
use of an ABI Prism 3700 capillary sequencer (Applied
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Biosystems). Fragment sizes were automatically assigned
by the GeneScan software (Applied Biosystems).
Statistical Analyses for Allelic Association
and Haplotype Analysis
Disease associations with SNP and indel markers were
initially assessed by the single-allele x2 test for a 2 # 2
contingency table, to compare each allele frequency in
patients with RA versus control individuals. Allele fre-
quencies were estimated by direct counting. When any
expected number of allele counts in the contin-2 # 2
gency table was !5, the P value was directly calculated
by Fisher’s exact test. The corrected P value, Pc, was not
calculated for SNP and indel markers, because they have
only two as the number of alleles. In microsatellitemark-
ers, as described elsewhere (Ota et al. 2001b), each phe-
notype frequency was compared, in patients with RA
versus control individuals, by the single-allele x2 test for
a contingency table. The Pc value was calculated2 # 2
for them as the P value multiplied by the number of
alleles. The odds ratio and the 95% CI were also cal-
culated for all markers. Pairwise haplotype frequencies
were calculated from two-locus–genotype data, by the
maximum-likelihood estimates, through use of the EH
(estimate haplotype frequencies) program (Terwilligerand
Ott 1994) (Web Resources of Genetic Linkage Analysis).
Haplotype frequencies were compared in patients with
RA versus control individuals and were evaluated, on
the basis of the haplotype counts calculated from the
estimated haplotype frequencies, by using the or2 # 4
contingency table. To calculate haplotype fre-2 # 2
quencies for adjacent-pairwise combinations for SNPs
(i.e., pairwise haplotypes between adjacent SNPs), we
employed only SNPs with 15% of allele frequencies in
each of two alleles both in patients with RA and in
control individuals. Any allele combination for two
SNPs next to each other created four haplotypes. Fre-
quencies of these haplotypes then were compared, in
the global test with 3 df, by using the contingency2 # 4
table. For association study of pairwise haplotypes be-
tween an adjacent microsatellite and SNP, the 2 # 2
contingency table was used. To examine whether geno-
type frequencies in the populations are in Hardy-Wein-
berg equilibrium, we performed the exact test of Hardy-
Weinberg proportion for multiple alleles, as provided by
Genepop software package (see Genepop on the Web)
(Guo and Thompson 1992). P values 1.05 were accepted
as nonsignificant deviation from Hardy-Weinberg equi-
librium.
Results
Identification of Sequence Variations in the Candidate
Segment for RA
Our previous study had reached the limits of the tools
available at that time, such that we could not refine the
target region further than the 70 kb bordered by the two
informative microsatellites (TNFa and C1-2-A) at the
telomeric end of the HLA class III region (fig. 1). Hence,
our first objective here was to identify sequence vari-
ations within this 70-kb candidate segment, to pinpoint
the causative gene among the four that are known to
be embedded in this segment—namely IkBL, ATP6G,
BAT1, and MICB (Browning and McMichael 1996;
MHC Sequencing Consortium 1999; Neville and Camp-
bell 1999; Bahram 2000). With regard toMICB, a large
number of intragenic SNPs have previously been re-
ported (Ando et al. 1997), with a provisional allele
number of 16 (designated as “MICB*001–MICB*016”)
(Bahram 2000). For the detection of sequence variations
in the three other genes (IkBL, ATP6G, and BAT1), PCR
products from their promoter/enhancer regions, the to-
tality of their exons, some of their introns (introns 1 and
2 of IkBL, introns 1 and 2 of ATP6G, and BAT1 introns
3, 5, and 8–11), and the 3′-flanking intergenic regions
(ATP6G and BAT1) (table 1 and fig. 1) were amplified
using genomic DNA from eight unaffected unrelated in-
dividuals and were subjected to nucleotide sequence anal-
ysis. In total, 12.2 kb of the 29.0 kb of genomic DNA
that contains IkBL and links it to BAT1 was sequenced
in each individual. Consequently, a total of 36 SNPs and
three indels were identified (table 2). This corresponds to
a density of one variation per every 685 bp, on aver-
age, in this 29.0-kb region. Among them, eight SNPs
(86446, 94619, 94636, 94678, 95429, 96652, a4909,
and a13808) and two indels (a13402 and a13736) are
novel variations identified in the present study. The other
SNPs and one indel have been reported previously (All-
cock et al. 1999a, 2001) or were already submitted to
dbSNP (see the Single-Nucleotide Polymorphism Web
site). Of all the SNPs reported here, three arewithin exons;
these are SNPs a13736 and a5160, in BAT1 3′ UTR and
exon 4, respectively, and SNP86352, in IkBL exon3 (with
the second and third of these SNPs being synonymous).
Association Study Using SNPs and Indels
Allele frequencies of a total of 35 SNPs and two indels
among the variations identified above (see the “Identi-
fication of Sequence Variations in the Candidate Segment
for RA” subsection) in the IkBL, ATP6G, and BAT1
genes (table 2) were compared between the patient and
unaffected control groups. As a result, statistically sig-
nificant ( ) positive associations with the diseaseP ! .05
were observed for six SNPs, as shown in table 2. Among
these, SNP 96452, a T/A substitution in the IkBL pro-
moter region (at nucleotide position 62 from the IkBL
transcription start site), wasmost significantly associated
with RA with a P value of .0062. The allele frequencies
of SNP 96452 were almost the same between females and
males among both the patients and the control individuals
Table 2
Nucleotide Variations Identified in and around the Second Susceptibility Region for RA and Results of Association Study Using
These Variations
SNP NAME (dbSNP
ACCESSION
NUMBER)a LOCATION
RELATIVE
DISTANCEb
(kb)
SNP
ALLELEc
ALLELE FREQUENCYd
ODDS RATIO (95% CI) x2e Pf
Patients
( )2np 232
Control Individuals
( )2np 200
69321 (rs1799724) TNFA promoter 7.0 G/A .302 .185 1.90 (1.21–3.00) 7.85 .0051
69327 (rs1800630) TNFA promoter 7.0 G/T .828 .800 1.20 (.74–1.95) .54 .4617
69495 (rs1799964) TNFA promoter 6.9 A/G .815 .785 1.20 (.75–1.93) .59 .4415
86352 (rs2230365) IkBL exon 3 10.0 C/T .703 .665 1.19 (.79–1.79) .70 .4016
86446 (ss4480593) IkBL intron 2 10.1 T/C .996 .995 1.16 (.07–18.76) … .9999
86481 (rs2239707) IkBL intron 2 10.1 C/T .625 .595 1.13 (.77–1.67) .41 .5236
86616 (rs3093949) IkBL intron 2 10.3 C/T .720 .640 1.45 (.96–2.17) 3.16 .0754
86695 (rs2857604) IkBL intron 2 10.3 G/A .302 .200 1.73 (1.11–2.70) 5.86 .0155
86948 (rs2857605) IkBL intron 2 10.6 T/C .224 .220 1.02 (.65–1.61) .01 .9178
94619 (ss4480594) IkBL intron 2 18.3 C/T .155 .155 1.00 (.59–1.69) .00 .9961
94636 (ss4480595) IkBL intron 2 18.3 G/A 1.000 .995 … … .4630
94678 (ss4480596) IkBL intron 2 18.3 T/C .858 .840 1.15 (.68–1.95) .26 .6067
95429 (ss4480597) IkBL intron 2 19.1 C/G .853 .845 1.07 (.63–1.81) .06 .8065
95993 (rs2071591) IkBL intron 1 19.6 G/A .720 .630 1.51 (1.01–2.26) 3.97 .0463
96029 (rs2239708) IkBL intron 1 19.7 A/T .853 .845 1.07 (.63–1.81) .06 .8065
96452 (rs2071592) IkBL promoter 20.1 T/A .720 .595 1.75 (1.17–2.61) 7.48 .0062
96652 (ss4480598) IkBL promoter 20.3 A/G .155 .115 1.41 (.81–2.48) 1.47 .2254
96714 (ss4480599) IkBL promoter 20.4 C/G .970 .930 2.42 (.96–6.12) 3.68 .0549
96818 (ss4480600) IkBL promoter 20.5 A insertion .082 .055 1.53 (.71–3.30) 1.20 .2728
97923 (rs2523502) ATP6G intron 2 21.6 A/T .082 .070 1.19 (.58–2.43) .22 .6425
98228 (rs2523503) ATP6G intron 2 21.9 G/T .828 .800 1.20 (.74–1.95) .54 .4617
98385 (rs2239705) ATP6G intron 2 22.0 C/T .293 .185 1.83 (1.16–2.88) 6.82 .0090
98988 (rs2071593) 3′-flanking region
of ATP6G
22.6 C/T .845 .835 1.08 (.64–1.80) .08 .7810
99067 (rs2071594) 3′-flanking region
of ATP6G
22.7 C/G .720 .625 1.54 (1.03–2.31) 4.41 .0357
a1682 (rs2239528) BAT1 promoter 25.3 C/T .772 .770 1.01 (.64–1.58) .00 .9695
a1785 (rs2523505) BAT1 promoter 25.4 G/C 1.000 .990 … … .2138
a1820 (rs2523506) BAT1 promoter 25.5 C/A .823 .795 1.20 (.74–1.94) .56 .4549
a2008 (rs2239527) BAT1 promoter 25.7 G/C .703 .615 1.48 (.99–2.21) 3.68 .0550
a4722 (rs2071595) BAT1 intron 2 28.4 C/G .159 .160 1.07 (.64–1.81) .00 .9883
a4909 (ss4480601) BAT1 intron 3 28.6 G/C 1.000 .990 … … .2138
a4930 (rs2523511) BAT1 intron 3 28.6 A/G .078 .055 1.45 (.67–3.14) .87 .3496
a4983 (rs2523512) BAT1 intron 3 28.6 C/T .828 .805 1.16 (.71–1.89) .37 .5448
a5040 (rs2516393) BAT1 intron 3 28.7 G/T .082 .075 1.10 (.54–2.23) .07 .7907
a5093 (rs2071596) BAT1 intron 3 28.7 C/T .711 .660 1.27 (.84–1.91) 1.31 .2522
a5136 (rs933208) BAT1 intron 3 28.8 A/C .806 .785 1.14 (.71–1.82) .29 .5883
a5160 (rs1129640) BAT1 exon 4 28.8 G/A .073 .055 1.36 (.62–2.97) .59 .4417
a7809g (rs2075580) BAT1 intron 5 31.5 G/C ND ND ND ND ND
a8086 (rs929138) BAT1 intron 5 31.7 G/A .319 .210 1.76 (1.14–2.97) 6.49 .0108
a13047 (rs2516478) BAT1 intron 9 36.7 T/C .828 .800 1.20 (.74–1.95) 1.38 .2402
a13402 (ss4480602) BAT1 intron 10 37.1 CT insertion ND ND ND ND ND
a13736 (ss4480603) BAT1 exon 11
(3′ UTR)
37.4 T deletion .875 .855 1.19 (.68–2.06) .37 .5432
a13808 (ss4480604) 3′-flanking region
of BAT1
37.5 G/A .996 .995 1.16 (.07–18.68) … .9999
NOTE.—ND p not determined.
a The name of each SNP is derived from nucleotide position of the SNP as detected starting from the first base on GenBank accession number
AP000505 (no prefix) or AP000506 (prefixed by “a”). For SNPs in dbSNP, see the Single Nucleotide Polymorphism Web site.
b Distance from the TNFa microsatellite.
c A nucleotide on the left-hand side of a slash mark (/) is a more frequent allele in the control individuals. Each SNP allele is represented by
the nucleotide sequence of the sense strand of each gene.
d Listed frequencies are higher in the patients than in the control individuals.
e With 1 df (here and in tables 3–5).
f P values !.05 that have been accepted as statistically significant are underlined. The P values of the SNPs for which there are no data given
for the odds ratio and/or x2 were directly calculated by Fisher’s exact test because the expected numbers in the table were !5.2# 2
g Association studies were not performed.
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Table 3
Association of TNFa and C1-2-A Alleles with RA
MICROSATELLITE
NAME (NO.
OF ALLELES)
MOST
STRONGLY
ASSOCIATED
ALLELE
PHENOTYPE FREQUENCY
ODDS RATIO (95% CI) x2 P Pc
Patients
( )np 116
Control Individuals
( )np 100
TNFa (13) 113 .353 .180 2.98 (1.91–4.64) 12.02 .00053 .0068
C1-2-A (13) 242 .629 .450 2.68 (1.82–3.94) 13.52 .00024 .0031
Table 4
Haplotype Association between TNFa or C1-2-A Microsatellites and SNPs
MICROSATELLITE SNP ESTIMATED HAPLOTYPE FREQUENCY
ODDS RATIO (95% CI) x2 PName Allele Name Allele
Patients
( )2np 232
Control Individuals
( )2np 200
TNFa 113 69321 A .156 .084 2.02 (1.11–3.69) 5.20 .023
TNFa 113 86695 A .156 .088 1.91 (1.06–3.46 ) 4.52 .034
TNFa 113 95993 C .177 .090 2.17 (1.22–3.87) 6.85 .0089
TNFa 113 96452 T .177 .090 2.17 (1.22–3.87) 6.85 .0089
TNFa 113 98385 T .146 .083 1.89 (1.03–3.48) 4.15 .042
TNFa 113 99067 C .175 .093 2.08 (1.17–3.70) 6.21 .013
TNFa 113 a8086 T .150 .087 1.85 (1.02–3.36) 4.00 .046
C1-2-A 242 69321 A .292 .168 2.04 (1.29–3.24) 9.21 .0024
C1-2-A 242 86695 A .292 .171 2.00 (1.27–3.17) 8.74 .0031
C1-2-A 242 95993 C .388 .221 2.24 (1.47–3.41) 14.01 .00018
C1-2-A 242 96452 T .388 .213 2.34 (1.53–3.58) 15.45 .000085
C1-2-A 242 98385 T .288 .160 2.12 (1.33–3.38) 9.93 .0016
C1-2-A 242 99067 C .388 .214 2.32 (1.52–3.54) 15.12 .00010
C1-2-A 242 a8086 T .297 .167 2.10 (1.33–3.33) 10.00 .0016
(data not shown). The MICB gene was also genotyped
for association study. Although the MICB*002 allele re-
vealed the most remarkable difference in allele frequency
between the patient and control groups, it did not reach
statistical significance ( ; 1 df; ). Three2x p 2.9 Pp .088
SNP markers (SNPs 69321, 69327, and 69495) in the
upstream region of the TNFA gene (nucleotide positions
1031, 863, and 857, respectively, in order from the
TNFA transcription initiation site), 5 kb centromerically
from our 70-kb candidate segment (fig. 1) (Matsushita et
al. 1999; Ota et al. 2001b), were also included in geno-
typing. The previous finding of a significant association
of SNP 69321, in the promoter/enhancer region of the
TNFA gene, was confirmed (Seki et al. 1999). However,
this does not represent a primary association but is due
to linkage disequilibrium with DRB1 alleles or SEs, as
described elsewhere (Higuchi et al. 1998; Matsushita et
al. 1999; Seki et al. 1999; Ota et al. 2001b). Furthermore,
the two microsatellites, C1-2-A and TNFa, which define
the boundaries of our critical segment, were also con-
firmed to be significantly associated with the disease (al-
leles 113 and 242, respectively) (table 3) despite the fact
that we dealt here with an unaffected population that
was different from that in our previous study (Ota et al.
2001b). Finally, all polymorphic markers investigated
here followed the Hardy-Weinberg equilibrium in both
patients and control individuals.
Association Study of Pairwise Haplotype
Frequencies of pairwise haplotypes consisting of C1-
2-A or TNFa and disease-associated SNPs alleles were
then investigated for comparison between the patient
and control groups, as listed in table 4. Both allele 113
of TNFa and allele 242 of C1-2-A revealed the strongest
association when combined with SNP 96452 (TNFa
; C1-2-A ), as expected. To pin-Pp .0089 Pp .000085
point the susceptible area more precisely, we calculated
the frequencies of all possible haplotypes with adjacent-
pairwise combinations for 34 SNP markers within the
critical segment, as well as for three SNP markers (SNPs
69321, 69327, and 69495) in the upstream region of
the TNFA gene, and these frequencies were then com-
pared between the patients and control individuals (fig.
2). The haplotype frequencies of all adjacent-pairwise
combinations were compared in the global test with 3
df. Remarkably strong associations were observed for
two haplotypes containing SNP 96452, namely SNP
96029–SNP 96452 ( ) and SNP 96452–SNPPp .0056
96652 ( ). Taken together, these data clearlyPp .00054
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Figure 2 Association study of pairwise haplotypes. Frequencies
of all possible haplotypes with adjacent-pairwise combinations were
calculated for 31 SNP markers (the frequencies of which were 15%
both in the patients and in the control individuals) within the 70-kb
RA critical segment between C1-2-A and TNFa, as well as for 3 SNP
markers (SNPs 69321, 69327, and 69495) in the upstream region of
the TNFA gene, were compared between the patients and control in-
dividuals. P values are dotted at the midpoint between two markers.
The horizontal bar indicates the distance (in kb) fromTNFa. Aphysical
map at bottom shows the location of genes in this region; symbols are
the same as in figure 1.
Table 5
Genotype Association between SNP 96452 and RA
GENOTYPE
GENOTYPE FREQUENCY
ODDS RATIO (95% CI) x2 P
Patients
( )np 116
Control Individuals
( )np 100
T/T .520 .340 2.08 (1.41–3.07) 6.86 .0088
T/A .412 .510 .65 (.45–.96) 2.38 .12
A/A .080 .150 .48 (.25–.90) 2.85 .091
define SNP 96452 in the IkBL promoter/enhancer region
as the second intra-MHC–locatedRA-susceptibility locus.
Genotype Frequency of SNP 96452 Alleles
Genotype frequencies of SNP 96452 alleles were in-
vestigated in the patient and unaffected control groups
(table 5). The frequency of the major genotype with a
T/T homozygosity was significantly higher in patients
with RA ( ) with an odds ratio of 2.08 (95%Pp .0088
CI 1.41–3.07) as compared to control individuals. Ac-
cordingly, this T allele is likely to increase the risk of the
prevalence of RA in the case of homozygosity, with a
recessive trait.
Discussion
Several recent genomewide scans in various populations
have confirmed the eminence of MHC genetics with re-
spect to RA susceptibility (Cornelis et al. 1998; Jawaheer
et al. 2001; MacKay et al. 2002). We have recently doc-
umented the existence of a second, HLA-DRB1–inde-
pendent, intra-MHC RA-susceptibility locus (Ota et al.
2001b). In the present study, to identify this second locus
(previously mapped to a 70-kb segment bordered by two
microsatellites at the telomeric end of the HLA class III
region), we systematically performed allele, pairwise
haplotype, and genotype association analyses of RAwith
respect to a total of 35 SNPs and two indels identified
in the IkBL, ATP6G, and BAT1 genes, as well as with
respect to MICB alleles. This investigation collectively
indicates that the T allele of SNP 96452 (T/A substi-
tution) located in the IkBL promoter region, at nucle-
otide position62 from the IkBL transcription start site,
is implicated in the development of RA. This conclusion
was also supported by the fact that the disease-associated
alleles of the two microsatellites, C1-2-A and TNFa,
which defined both ends of the RA-susceptibility locus
(Ota et al. 2001b), were in linkage disequilibrium with
the T allele of SNP 96452.
Although the biological function of the putative IkBL
protein is, at this point, mostly speculative, its similarity
to IkBa in the sequence (Browning andMcMichael 1996)
and the cellular localization (Semple et al. 2002), which
regulates the nuclear localization of NFkB (a nuclear fac-
tor that stimulates the transcription of many immuno-
logically and inflammatory relevant genes, including cy-
tokines such as the closely linked TNF-a; for review, see
Ghosh et al. 1998), presumes analogous function. To
investigate the functional consequence of our SNP,
which lies within the putative regulatory region of
IkBL, we scanned the DNA segment containing and
extending this site through use of the TFSearch pro-
gram (see the TFSearch Web site). This search revealed
that the nucleotide sequence surrounding the RA-
susceptible allele—that is, the T allele of SNP 96452
(62T) (CTCCACCTGCG)—is indeed a putative bind-
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ing site for the transcription factor dEF1, as previous-
ly proposed by Allcock et al. (2001). In contrast, the
nonsusceptible allele, the A allele of SNP 96452
(62A), is likely to disrupt this motif for dEF1. In fact,
examination of 41 known dEF-binding sites showed
that all contained a T nucleotide at this position (Sekido
et al. 1994). Because dEF1 is a transcription repressor
involved in skeletal and T-cell development (Takagi et
al. 1998), it is reasonable to speculate that62T/Amay
somehow affect the transcriptional promoter activity,
altering the immune response in the development of RA.
Allcock et al. (2001) did investigate the effect that the
62T/A SNP has on the transcription level of IkBL
mRNA by using Epstein-Barr virus–transformed B-lym-
phoblastoid cells, but they did not observe any differ-
ence of IkBL mRNA level between the A and T alleles
at position 62. However, it is likely that B-cell lines
do not represent the best in vitro model for the reca-
pitulation of the affected inflammatory joints in RA,
and further analysis in different cell lines and, more
importantly, in situ may reveal the biological conse-
quence of this promoter dimorphism. de la Concha et
al. (2000) reported an association between a structural
SNP at amino acid position 224 of the IkBL molecule,
which is predicted to be the protein kinase C phos-
phorylation site (Albertella et al. 1994), and suscepti-
bility to ulcerative colitis. These findings raise the pos-
sibility that the IkBL protein interacts with NFkB, so
transcription-level changes depending on the promoter-
based diallelic polymorphism may affect diverse im-
munological processes and may predispose one to a
number of major autoimmune diseases linked to the
MHC. It is perhaps relevant that a second susceptibility
locus for multiple sclerosis, as well as for type I diabetes
and celiac disease, has also been mapped to this telo-
meric part of the MHC (Allcock et al. 1999b; Lie et al.
1999a, 1999b).
In summary, we pinpoint the MHC class III–located
IkBL protein as the second, class II–independent, intra-
MHC RA-susceptibility locus. Although little is known
about the function of IkBL per se, its similarity to IkBa
infers similar function (i.e., involvement in the silencing
of NFkB functionality). NFkB, a pivotal nuclear factor,
activates the transcription of many important genes in-
volved in immune and inflammatory responses (for re-
view, see Ghosh et al. 1998) and is piloted by a variety
of extracellular signals, most importantly those that trig-
ger the innate immune system. Hence, the MHC may
encode RA predisposition through the innate and adap-
tive components of the immune system. Hence, the recent
report of the involvement of both innate and adaptive
effectors of the immune system in a genetically engineered
animal model of RA may be relevant to this observation
(Ji et al. 2002). Finally, further analysis may implicate
structural or regulational IkBL diversity in other MHC-
linked autoimmune diseases. The emergence of IkBL from
the densely packed MHC class III loci may now help to
focus our attention on its biology, a goal we shall pursue
through the creation of IkBL-transgenic and -knockout
mice, which may open novel pathophysiological insights,
as well as therapeutic areas of intervention for RA and
other autoimmune conditions.
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